Eluxadoline, also known as JNJ-27018966, is a novel, orally-active drug approved for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D). It was approved for use by the United States Food and Drug Administration on May 27, 2015. Eluxadoline is a μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist that acts locally in the enteric nervous system, possibly decreasing adverse effects on the central nervous system. This product is discintinued (DEA Schedule IV).
Anon. Crystalline forms of methyl 5-(((S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)-N-((S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl)propanamido)methyl)-2-methoxybenzoate dihydrochloride. Volume 16. Issue 4A. Pages 1-3. (Journal; Patent)
Anon. Process for the preparation of (S)-2-((tert-butoxycarbonyl) amino)-3-(4-carbamoyl-2,6 dimethylphenyl) propanoic acid. Volume 15 Issue 11A Pages 1pp.(Journal; Patent)
Inamdar, Murad Ismail; Mohan, Sriram Hari; Hirpara, Ketan Vithalbhai. Processes for the preparation of eluxadoline. WO 2018055528. (Assignee Sun Pharmaceutical Industries Limited, India)
Chen, Minhua; Zhang, Yanfeng; Liu, Kai; Lu, Fei; Ji, Shulin; Zhang, Liang; Yang, Chaohui. New crystal form of eluxadoline and preparation method thereof. WO 2017114446. (Assignee Crystal PharmaTech Co., Ltd., Peop. Rep. China)
Rajan, Srinivasan Thirumalai; Eswaraiah, Sajja; Reddy, Sagyam Rajeshwar; Prabhakar, Macharla; Rajesham, Boge. Process for the preparation of 5-[[[(2S)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4 -phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid and its polymorphs. WO 2017191650. (Assignee MSN Laboratories Private Limited, India)
Mawale, Vishal Sukhadeo; Mahakal, Kumodini Kashinath; Mahajan, Pravin Raghunath; Singh, Gurvinder Pal; Ray, Purna Chandra; Singh, Girij Pal; Rajput, Lalitkumar Dilipsing; Shivdavkar, Radhakrishna Bhikaji. Process for the preparation of Eluxadoline. Assignee Lupin Limited, India. WO 2018020450. 2018.
